drugset
drugset / Trial / NCT05704556

Evaluation of the Pharmacokinetics and Safety of VX-548 in Participants With Renal Impairment

NCT05704556 ↗

Phase 1 Completed 38 enrolled Vertex Pharmaceuticals Incorporated
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the pharmacokinetics (PK), safety, and tolerability of VX-548 and its metabolite in participants with severe or moderate renal impairment and healthy participants.

Timeline

Start
2023-02-27
Primary completion
2024-03-30
Completion
2024-03-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Suzetrigine Small molecule — Oral

Indications

No indication recorded.